Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

PERKINELMER, INC.

(PKI)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
11/22/2021 11/23/2021 11/24/2021 11/26/2021 11/29/2021 Date
181.76(c) 179.62(c) 176.95(c) 183.09(c) 183.43 Last
922 815 712 322 1 015 198 633 271 9 965 Volume
-3.74% -1.18% -1.49% +3.47% +0.19% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 4 922 M - -
Net income 2021 951 M - -
Net Debt 2021 4 157 M - -
P/E ratio 2021 22,3x
Yield 2021 0,15%
Sales 2022 4 258 M - -
Net income 2022 631 M - -
Net Debt 2022 3 499 M - -
P/E ratio 2022 36,5x
Yield 2022 0,15%
Capitalization 23 106 M 23 106 M -
EV / Sales 2021 5,54x
EV / Sales 2022 6,25x
Nbr of Employees 14 000
Free-Float 99,8%
More Financials
Company
PerkinElmer, Inc. is a provider of products, services and solutions for the diagnostics, life sciences and applied markets. The Company operates through two segments: Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment provides products and services targeted towards the life sciences and applied markets. The Diagnostics segment develops diagnostics, tools and applications... 
Sector
Advanced Medical Equipment & Technology
Calendar
12/01 | 10:30amPresentation
More about the company
Ratings of PerkinElmer, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B-
More Ratings
All news about PERKINELMER, INC.
11/22PerkinElmer, Inc. Launches Cloud Based Solution to Enable Remote Lab Management
CI
11/16PerkinElmer to Present at Evercore ISI HealthCONx Conference 2021
BU
11/09PERKINELMER INC Management's Discussion and Analysis of Financial Condition and Result..
AQ
11/05PerkinElmer to Present at 2021 Stifel Healthcare Conference
BU
11/04BioLegend, Inc. and subsidiaries Index to financial statements - Form 8-K/A
PU
11/04PERKINELMER INC Completion of Acquisition or Disposition of Assets, Financial Statemen..
AQ
11/04PerkinElmer, Inc. agreed to acquire 27.5% stake in YuanDian Biolabs Co., LTD for $5.5 m..
CI
11/03Stifel Adjusts Price Target on PerkinElmer to $187 From $175, Maintains Buy Rating
MT
11/03JPMorgan Adjusts Price Target on PerkinElmer to $180 From $168, Maintains Neutral Ratin..
MT
11/03Wells Fargo Adjusts Price Target on PerkinElmer to $200 from $190, Keeps Overweight Rat..
MT
11/03Baird Adjusts PerkinElmer's Price Target to $206 From $183, Keeps Outperform Rating
MT
11/02PerkinElmer Fiscal Q3 Adjusted EPS, Revenue Advance; Company Boosts FY Outlook
MT
11/02PERKINELMER : Q3 Earnings Snapshot
AQ
11/02PerkinElmer Announces Financial Results for the Third Quarter of 2021 - Form 8-K
PU
11/02PERKINELMER INC : Results of Operations and Financial Condition (form 8-K)
AQ
More news
News in other languages on PERKINELMER, INC.
11/02PerkinElmer augmente son bénéfice par action ajusté et son chiffre d'affaires au troisi..
11/02Earnings Flash (PKI) PERKINELMER annonce un chiffre d'affaires de 1,17 milliard de doll..
10/27PerkinElmer, Inc. Déclare un dividende trimestriel régulier, payable le 11 février 2022
10/18Hamid Erfanian est nommé directeur général d'Enzo Biochem
10/07PerkinElmer reçoit l'autorisation d'utilisation d'urgence de la FDA pour le test COVID-..
More news
Analyst Recommendations on PERKINELMER, INC.
More recommendations
Stock Trading Strategies
PERKINELMER, INC. - 05/17
Technically solid
BUY
More Stock Trading Analysis
Chart PERKINELMER, INC.
Duration : Period :
PerkinElmer, Inc. Technical Analysis Chart | PKI | US7140461093 | MarketScreener
Technical analysis trends PERKINELMER, INC.
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 12
Last Close Price 183,09 $
Average target price 185,27 $
Spread / Average Target 1,19%
EPS Revisions
Managers and Directors
Prahlad Ramadhar Singh President, CEO, COO & Director
James M. Mock Chief Financial Officer & Senior Vice President
Alexis Platon Michas Non-Executive Chairman
Joel S. Goldberg Secretary, SVP-Administration & General Counsel
Peter Barrett Independent Director
Sector and Competitors